Thomas Lundbäck

4.8k total citations · 1 hit paper
61 papers, 2.8k citations indexed

About

Thomas Lundbäck is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Thomas Lundbäck has authored 61 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 12 papers in Oncology and 9 papers in Genetics. Recurrent topics in Thomas Lundbäck's work include Peptidase Inhibition and Analysis (8 papers), Biochemical and Molecular Research (7 papers) and DNA and Nucleic Acid Chemistry (7 papers). Thomas Lundbäck is often cited by papers focused on Peptidase Inhibition and Analysis (8 papers), Biochemical and Molecular Research (7 papers) and DNA and Nucleic Acid Chemistry (7 papers). Thomas Lundbäck collaborates with scholars based in Sweden, United Kingdom and Japan. Thomas Lundbäck's co-authors include Hanna Axelsson, Helena Almqvist, P. Nordlund, Rozbeh Jafari, Daniel Martinez Molina, Marina Ignatushchenko, Torleif Härd, Stefan Knapp, Rudolf Ladenstein and Brinton Seashore‐Ludlow and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Thomas Lundbäck

60 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The cellular thermal shift assay for evaluating drug target interactions in cells

2014 986 citations Rozbeh Jafari, Helena Almqvist et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Lundbäck Sweden	26	2.0k	423	320	263	242	61	2.8k
Antonio Pineda‐Lucena Spain	34	2.3k 1.2×	419 1.0×	241 0.8×	145 0.6×	179 0.7×	127	3.3k
F. Niesen United Kingdom	19	2.7k 1.4×	422 1.0×	211 0.7×	209 0.8×	261 1.1×	25	3.5k
Abdellah Allali‐Hassani Canada	34	3.3k 1.7×	405 1.0×	220 0.7×	140 0.5×	247 1.0×	60	4.1k
Christina Kiel Spain	26	2.6k 1.3×	329 0.8×	161 0.5×	509 1.9×	194 0.8×	60	3.4k
Shozeb Haider United Kingdom	37	3.7k 1.9×	323 0.8×	323 1.0×	147 0.6×	183 0.8×	141	4.7k
Anang A. Shelat United States	30	1.7k 0.9×	446 1.1×	447 1.4×	417 1.6×	173 0.7×	82	2.9k
Seungil Han United States	27	1.6k 0.8×	401 0.9×	261 0.8×	96 0.4×	193 0.8×	50	2.8k
Daniel Martinez Molina Sweden	16	3.1k 1.6×	605 1.4×	395 1.2×	527 2.0×	153 0.6×	20	4.3k
Grzegorz M. Popowicz Germany	33	2.3k 1.2×	822 1.9×	581 1.8×	217 0.8×	132 0.5×	101	3.3k
Yuk Y. Sham United States	31	2.2k 1.1×	293 0.7×	625 2.0×	182 0.7×	133 0.5×	85	3.2k

Countries citing papers authored by Thomas Lundbäck

Since Specialization

Citations

This map shows the geographic impact of Thomas Lundbäck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Lundbäck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Lundbäck more than expected).

Fields of papers citing papers by Thomas Lundbäck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Lundbäck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Lundbäck. The network helps show where Thomas Lundbäck may publish in the future.

Co-authorship network of co-authors of Thomas Lundbäck

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Lundbäck. A scholar is included among the top collaborators of Thomas Lundbäck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Lundbäck. Thomas Lundbäck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Villoutreix, Bruno O., Magdalena Otrocka, Anna‐Lena Gustavsson, et al.. (2025). Targeting TUBG1 in RB1 ‐negative tumors. The FASEB Journal. 39(5). e70431–e70431.

Miljković, Filip, Scott Davies, Karolina Kwapień, et al.. (2024). Closing the Design–Make–Test–Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability. Journal of Medicinal Chemistry. 67(22). 20242–20257. 6 indexed citations

Johansson, Lars, Eldar Abdurakhmanov, Nils Landegren, et al.. (2022). Monitoring drug–target interactions through target engagement-mediated amplification on arrays and in situ. Nucleic Acids Research. 50(22). e129–e129. 3 indexed citations

Kalsum, Sadaf, Magdalena Otrocka, Blanka Andersson, et al.. (2022). A high content screening assay for discovery of antimycobacterial compounds based on primary human macrophages infected with virulent Mycobacterium tuberculosis. Tuberculosis. 135. 102222–102222. 5 indexed citations

Salomons, Florian A., Martin Haraldsson, Lotta Elfman, et al.. (2021). Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound. Cell Death and Disease. 12(10). 914–914. 2 indexed citations

Reshma, R., Thomas Lundbäck, Hanna Axelsson, et al.. (2020). A FabG inhibitor targeting an allosteric binding site inhibits several orthologs from Gram-negative ESKAPE pathogens. Bioorganic & Medicinal Chemistry. 30. 115898–115898. 18 indexed citations

Axelsson, Hanna, Helena Almqvist, Magdalena Otrocka, et al.. (2018). In Situ Target Engagement Studies in Adherent Cells. ACS Chemical Biology. 13(4). 942–950. 21 indexed citations

Lewis, Andrew M., Daniel Conole, Sébastien R. G. Galan, et al.. (2018). Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors. ACS Chemical Biology. 13(10). 2849–2854. 13 indexed citations

Llona‐Minguez, Sabin, Maria Häggblad, Ulf Märtens, et al.. (2017). Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 2: Pyridone- and pyrimidinone-derived systems. Bioorganic & Medicinal Chemistry Letters. 27(15). 3219–3225. 5 indexed citations

10.

Llona‐Minguez, Sabin, Andreas Höglund, Elisée Wiita, et al.. (2017). Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1. Journal of Medicinal Chemistry. 60(5). 2148–2154. 18 indexed citations

11.

Rosenström, Ulrika, Hanna Axelsson, Leif Dahllund, et al.. (2016). Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule Screening. Assay and Drug Development Technologies. 14(3). 180–193. 18 indexed citations

12.

Diwakarla, Shanti, Erik Nylander, Alfhild Grönbladh, et al.. (2016). Binding to and Inhibition of Insulin-Regulated Aminopeptidase by Macrocyclic Disulfides Enhances Spine Density. Molecular Pharmacology. 89(4). 413–424. 37 indexed citations

13.

Seashore‐Ludlow, Brinton & Thomas Lundbäck. (2016). Early Perspective. SLAS DISCOVERY. 21(10). 1019–1033. 23 indexed citations

14.

Glickman, J. Fraser, Thomas Lundbäck, Andrew D. Napper, et al.. (2014). Controversies in ASSAY and Drug Development Technologies : A Focus on Assessing Irreproducibility. Assay and Drug Development Technologies. 12(8). 443–451. 1 indexed citations

15.

Sävmarker, Jonas, et al.. (2014). Microwave Heated Flow Synthesis of Spiro-oxindole Dihydroquinazolinone Based IRAP Inhibitors. Organic Process Research & Development. 18(11). 1582–1588. 38 indexed citations

16.

Theorell, Jakob, Anna‐Lena Gustavsson, Bianca Tesi, et al.. (2014). Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation. Cancer Immunology Immunotherapy. 63(6). 627–641. 25 indexed citations

17.

Lehmann, Fredrik, Eva Axén, J. Uppenberg, et al.. (2004). Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorganic & Medicinal Chemistry Letters. 14(17). 4445–4448. 71 indexed citations

18.

Jensen, Henrik, et al.. (2004). On the Nature of Solvent Effects on Redox Properties. The Journal of Physical Chemistry A. 108(21). 4805–4811. 40 indexed citations

19.

Baumann, Herbert, Stefan Knapp, Thomas Lundbäck, Rudolf Ladenstein, & Torleif Härd. (1994). Solution structure and DNA-binding properties of a thermostable protein from the archaeon Sulfolobus solfataricus. Nature Structural Biology. 1(11). 808–819. 142 indexed citations

20.

Lundbäck, Thomas, Carol Cairns, Jan-Ακε Gustafsson, Jan Carlstedt‐Duke, & Torleif Härd. (1993). Thermodynamics of the glucocorticoid receptor-DNA interaction: Binding of wild-type GR DBD to different response elements. Biochemistry. 32(19). 5074–5082. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact